Overview
Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis
Status:
Completed
Completed
Trial end date:
2012-08-01
2012-08-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This clinical trial compares a combination of two drugs that constrict blood vessels (Octreotide LAR and Midodrine) to albumin after large volume paracentesis. Subjects have cirrhosis and ascites.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
US Department of Veterans Affairs
VA Office of Research and DevelopmentTreatments:
Midodrine
Octreotide
Vasoconstrictor Agents
Criteria
Inclusion Criteria:- Cirrhosis of any etiology
- Age 18-80 years
- Moderate to severe ascites
Exclusion Criteria:
- No or small ascites
- Severe hepatic hydrothorax
- Recent GI (gastrointestinal) hemorrhage
- Active bacterial infection
- Cardiac failure
- Organic renal disease
- Hepatocellular carcinoma
- Severe comorbidity (advanced neoplasia)
- Serum creatinine > 3 mg/dl
- Pregnancy